CPRXThe headline: sales are still climbing
Catalyst Pharmaceuticals kicked out first-quarter 2026 results on May 11th, and the main takeaway is pretty simple: the business kept growing, and it did it without leaning on debt like a college kid leaning on a credit card.
Revenue came in at $149.4 million, helped by a 28% year-over-year jump in net product revenues from FIRDAPSE and AGAMREE. That’s the kind of number investors like because it suggests the core commercial engine is still humming, not just sputtering along on one-off noise.
Why your inner shareholder should care
A few details stand out:
- Cash and cash equivalents were $755.9 million at March 31, 2026
- The company had no funded debt
- Product revenue growth was broad enough to keep the story from feeling fragile
That combo matters. When a mid-cap pharma company has real growth and a fortress-like balance sheet, it gives management more room to keep investing, buying back time, and maybe making a move or two if the right opportunity pops up.
Big picture
Catalyst doesn’t need to wow anyone with moon-shot hype here. It just needs to keep converting approved drugs into steady revenue, and this quarter says it’s still doing exactly that. For investors, that’s less fireworks, more sturdy compounder vibes — and honestly, in biotech, that’s not a bad problem to have.